Experience

RAPT Therapeutics

• Biotechnology Research
• 100 - 200 Employee

• Scientist I

  • Jan 2022 - Present

  San Francisco Bay Area

• Associate Scientist

  • Jan 2019 - Present

  San Francisco Bay Area

• Research Associate III

  • Nov 2017 - Jan 2019

  San Francisco Bay Area


FLX Bio, Inc.
• United States
• Biotechnology
• R&D Medicinal Chemist

  • Nov 2017 - Present


Yumanity Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Staff Scientist

  • Dec 2015 - Nov 2017

  Cambridge, MA



H3 Biomedicine

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Research Associate

  • Nov 2012 - Nov 2015

  Cambridge, MA *Designed and synthesized splicing modulators specifically targeting the mutant SF3B complex for aberrant pre-mRNA splicing inhibition. *Route development, optimization, scale-up of chiral intermediates and lead compounds ensured timely entry to in vivo PK/PD, ATD/MTD and efficacy studies. *Route optimization and design efforts led to inclusion on one patent as co-inventor. *Collaborated with the process chemistry group to provide a scalable route towards an advanced chiral… Show more *Designed and synthesized splicing modulators specifically targeting the mutant SF3B complex for aberrant pre-mRNA splicing inhibition. *Route development, optimization, scale-up of chiral intermediates and lead compounds ensured timely entry to in vivo PK/PD, ATD/MTD and efficacy studies. *Route optimization and design efforts led to inclusion on one patent as co-inventor. *Collaborated with the process chemistry group to provide a scalable route towards an advanced chiral intermediate en route to the clinical candidate. Show less



Roche

• Switzerland
• Biotechnology Research
• 700 & Above Employee

• Senior Research Associate

  • Sep 2011 - Nov 2012

  Nutley, NJ *Synthesis route design and optimization efforts around two high throughput screening (HTS) fragment hits led to a lead series identification (LSI) within twelve months. Molecular design for improving potency and PK properties led to inclusion on 1 patent. *Patent work stream committee chemistry representative. *Evaluated the feasibility of colorimetric detection based assays and LC/MS assisted detection of formaldehyde conjugates.

• Research Associate III

  • Jan 2007 - Aug 2011

  Palo Alto, CA *Synthesis route design and exploratory optimization efforts using a focused library quickly resulted in the selection of a chemical lead series for the JNK program. *Hit optimization and design efforts contributed to two lead compounds and inclusion on two patents. *Fine-tuned and validated the synthetic route to an advanced intermediate. The route was adopted by the process group for the production of 2 kg of API (active pharmaceutical ingredient) for in vivo GLP toxicology studies.

• Research Associate II

  • Apr 2001 - Dec 2006

  Palo Alto, CA *Research centers on the synthesis of small molecules as therapeutic agents for the suppression of inflammation; molecular targets include cathepsin K, JNK, and P38.



Dupont-Merck

• United States
• Hospitals and Health Care

• Associate Chemist

  • 1997 - 1998

  Research centered on the synthesis of corticotrophin-releasing hormone antagonists. My analoging efforts centered on the side-chain tolerance of pyrazolotriazine and imadazopyrazole cores.



Leiden University

• Netherlands
• Higher Education
• 700 & Above Employee

• summer research exchange student

  • Jun 1996 - Aug 1996

  Summer Research Exchange Program: Supervisors: Dr. Rutger Boers and Dr. Johan Lugtenburg Multi-gram synthesis of decaprenyl isoprenoid tails and methylbutynoate for the total synthesis of 13C labeled ubiquinones and plastoquinones.